Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
- Design
- Randomized trial · Biomarker outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all participants had obesity or overweight (mean BMI 35.4 in Study 1 and 37.4 in Study 2), and Study 1 participants also had type 2 diabetes.
- Could weight loss explain it?
- PossiblyThe abstract reports placebo-adjusted biomarker changes but gives no weight or HbA1c results and no adjustment for them, so weight loss or metabolic improvement could explain part of the effect; no cached full text.
- Study tier
- Study tier 3LOW: post hoc biomarker analysis of two randomised, double-blind, placebo-controlled phase 2 trials, with no clinical outcomes and no sample size in the abstract.
- Assessment
- Version 4 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This post hoc analysis of two randomised, double-blind, placebo-controlled phase 2 trials studied adults with obesity or overweight, with type 2 diabetes (Study 1) or without it (Study 2). Retatrutide was linked to lower atherogenic blood fats in both trials, for example apolipoprotein B -21.4% and -24.2%. The inflammation markers hsCRP (-54.8%) and IL-6 (-29.6%) fell in Study 2 but not in Study 1. These are blood markers, not heart attacks or strokes.
01Findings
What the study reported
- Drugs
- Retatrutide
- Dose
- Study 1: 0.5/4/8/12 mg once weekly; Study 2: 1/4/8/12 mg
- Comparator
- placebo (both studies); dulaglutide 1.5 mg (Study 1)
- Treatment duration
- 36 weeks (Study 1); 48 weeks (Study 2)
- Primary outcome
- placebo-adjusted change from baseline in lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory biomarkers (post hoc)
- Effect
- Non-HDL cholesterol up to -21.0% (Study 1) and up to -26.9% (Study 2); apolipoprotein B -21.4% and -24.2%; small LDL particles -32.6% and -32.3%; hsCRP -54.8% and IL-6 -29.6% in Study 2, not significant in Study 1
- 95% confidence interval
- Not extracted
- P value
- false discovery rate-adjusted p < 0.05 (significance threshold; exact values not given)
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- Post hoc analysis of two phase 2 trials with biomarker outcomes only; the abstract gives no sample size or confidence intervals, inflammatory marker reductions were seen in Study 2 but not Study 1, and all participants had obesity or overweight.
Who was studied
- Bmi mean
- 35.4 kg/m2 (Study 1); 37.4 kg/m2 (Study 2)
- Obesity status
- required (obesity/overweight; BMI threshold not stated)
- Diabetes status
- mixed (Study 1 type 2 diabetes required; Study 2 without type 2 diabetes)
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- obesity/overweight, with or without type 2 diabetes
- Inclusion exclusion
- adults with obesity/overweight; Study 1 with type 2 diabetes, Study 2 clinical obesity without type 2 diabetes
Study quality details
- Study design
- Randomized controlled trial
- Sample size
- not extracted
- Randomization
- yes
- Blinding
- double-blind
- Comparator
- placebo (both studies); dulaglutide 1.5 mg (Study 1)
- Follow up duration
- not stated
- Outcome type
- biomarker
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported in abstract; significance set at false discovery rate-adjusted p < 0.05; post hoc analysis
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[AIMS] To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). [MATERIALS AND METHODS] Data were analysed from two randomised, double-blind, placebo-controlled phase 2 trials. In Study 1, adults with obesity/overweight and T2D received once-weekly retatrutide (0.5/4/8/12 mg), dulaglutide (1.5 mg) or placebo for 36 weeks; in Study 2, adults with clinical obesity without T2D received retatrutide (1/4/8/12 mg) or placebo for 48 weeks. Fasting blood samples were collected at baseline and during treatment to assess lipids, apolipoproteins, lipoprotein particle subclasses and inflammatory biomarkers. Mixed models for repeated measures estimated placebo-adjusted change from baseline. Statistical significance was defined as a false discovery rate-adjusted p < 0.05. [RESULTS] Mean body mass index was 35.4 kg/m2 (Study 1) and 37.4 kg/m2 (Study 2). In both studies, retatrutide was associated with significant reductions in non-high-density lipoprotein cholesterol (Study 1: up to -21.0%, Study 2: up to -26.9%), apolipoprotein B (-21.4%, -24.2%), total triglyceride-rich lipoprotein particles (-22.5%, -33.7%), large triglyceride-rich lipoprotein particles (-84.4%, -76.6%), triglyceride-rich lipoprotein cholesterol (-29.4%, -38.6%), total low-density lipoprotein particles (-19.7%, -23.5%) and small low-density lipoprotein particles (-32.6%, -32.3%). Retatrutide was associated with significant reductions in high-sensitivity C-reactive protein (-54.8%) and interleukin-6 (-29.6%) in Study 2 but not Study 1. [CONCLUSIONS] In adults with obesity/overweight, with or without T2D, retatrutide treatment was associated with reductions in atherogenic lipoproteins and inflammatory biomarkers linked to cardiovascular disease risk. [TRIAL REGISTRATION] ClinicalTrials.gov numbers NCT04881760 and NCT04867785.